Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases - Report - MDSpire

Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases

  • By

  • Xiaodan Shen

  • Caiji Zheng

  • Renyong Lin

  • Juan Wang

  • Zheng Chen

  • June 2, 2026

  • 0 min

Share

Clinical Report: Advancements in Understanding Gut Metabolites and Their Role

Overview

Gut-derived metabolites are crucial in regulating neuroimmune inflammatory diseases by influencing immune modulation and CNS responses. Key metabolites like short-chain fatty acids (SCFAs) and bile acids exhibit both protective and harmful effects, highlighting the need for targeted therapeutic strategies.

Background

The interplay between gut microbiota and the central nervous system (CNS) is increasingly recognized as vital in neuroimmune inflammatory disorders such as multiple sclerosis and Alzheimer's disease. Dysbiosis and altered metabolite profiles can exacerbate these conditions, emphasizing the importance of understanding gut-derived metabolites in disease pathogenesis. This knowledge may lead to innovative therapeutic approaches targeting the gut-immune-brain axis.

Data Highlights

No specific numerical data or trial results were provided in the article.

Key Findings

  • Gut metabolites, particularly SCFAs, promote Treg differentiation and exert anti-inflammatory effects.
  • Bile acids can have a dual role, with some promoting inflammation while others have protective effects.
  • Dysbiosis is linked to neuroimmune inflammatory diseases, indicating a metabolite imbalance in conditions like MS and AD.
  • Novel therapeutic strategies are emerging that target the gut-immune-brain axis through immune-centric and microbiota-centric approaches.
  • Future research should focus on the molecular interactions between metabolites and immune cells to enhance treatment strategies.

Clinical Implications

Healthcare professionals should consider the role of gut metabolites in the management of neuroimmune inflammatory diseases. Interventions aimed at restoring gut microbiota balance may provide new avenues for treatment, although further research is necessary to validate these approaches.

Conclusion

Understanding the role of gut metabolites in neuroimmune inflammatory diseases opens new therapeutic possibilities. Continued research is essential to translate these findings into clinical practice.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Host-microbe immunometabolic chat: a new era of organismal communication
  2. Brain, 2025 -- Exploring GABA Signaling Pathways within the Brain-Gut-Microbiome Interconnection
  3. Frontiers in Immunology, 2026 -- Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets
  4. Journal of Gastroenterology, 2019 -- Modifying Gut Microbiota to Improve Immune Regulation in the Treatment of Inflammatory Bowel Diseases
  5. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis - UCL Discovery
  6. Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease - PMC
  7. Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profile - PubMed
  8. Fasting, ketogenic, and anti-inflammatory diets in multiple sclerosis: a randomized controlled trial with 18-month follow-up - PubMed
  9. Alteration of bile acid profile in patients with neuromyelitis optica spectrum disorders and multiple sclerosis - ScienceDirect
  10. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis - UCL Discovery
  11. Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease - PMC
  12. Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profile - PubMed
  13. Fasting, ketogenic, and anti-inflammatory diets in multiple sclerosis: a randomized controlled trial with 18-month follow-up - PubMed
  14. Alteration of bile acid profile in patients with neuromyelitis optica spectrum disorders and multiple sclerosis - ScienceDirect

Original Source(s)

Related Content